How to Succeed on GLP-1 Medications: What the Science Says

*Compounded semaglutide and tirzepatide are not FDA-approved. This article is for educational and informational purposes only and does not constitute medical advice. Individual results vary. Consult your licensed healthcare provider before starting any medication or making changes to your treatment plan.*

---

GLP-1 medications like semaglutide and tirzepatide have produced some of the most consistent weight loss results in the history of obesity medicine. In pivotal trials, participants lost an average of 15% to 21% of their body weight. Yet in the real world, a significant portion of people stop taking these medications within months, often before seeing those results.

So what separates the patients who achieve meaningful, lasting weight loss from those who discontinue early? The answer involves biology, behavior, expectation management, and support systems. This article breaks down the evidence-backed factors that predict success and what you can do to improve your own outcomes.

---

The Real-World Adherence Gap

The clinical trial numbers are compelling, but clinical trials select for motivated participants who receive close monitoring and support. Real-world adherence looks different.

A 2026 retrospective analysis published in Diabetes, Obesity and Metabolism followed 1,374 adults who were newly dispensed a GLP-1 medication (semaglutide or liraglutide). Within 180 days, 31.7% of those patients had discontinued therapy entirely. [1]

The most common documented reasons for stopping:

• Adverse drug reactions (26.8%), primarily nausea and gastrointestinal symptoms
• Cost concerns (14.4%)
• Non-adherence unrelated to side effects (11.2%)

That means nearly one in three people stopped their medication within six months, before most of the meaningful weight loss has had time to occur. GLP-1 medications work through a slow, progressive mechanism. Discontinuing early is one of the clearest predictors of not achieving long-term results.

---

What Consistent Use Actually Achieves

Here is why sticking with the medication matters so much. A 2025 narrative review in Diabetes, Obesity and Metabolism examined real-world evidence across multiple GLP-1 therapies and found that outcomes in clinical practice tend to be lower than those seen in randomized trials. The critical qualifier: when the analysis focused specifically on highly adherent patients, real-world outcomes approached the results seen in controlled trial settings. [2]

The STEP 1 trial, the landmark semaglutide study that established the drug's efficacy, found a mean weight loss of 14.9% over 68 weeks among participants receiving semaglutide 2.4 mg weekly. About 30% of participants lost 15% or more of their body weight, and roughly 14% achieved 20% or greater weight loss. [3]

These results are for the FDA-approved branded formulation (Wegovy) studied in a controlled clinical trial. Compounded semaglutide has not been separately studied in equivalent trials, and branded trial results should not be assumed to apply to compounded formulations.

That range, from modest responders to exceptional ones, reflects real biological variation. But the critical shared feature among high responders was consistent use at therapeutic doses over time. You cannot know which responder category you are in until you have given the medication a genuine, sustained trial.

---

Factor 1: Managing Side Effects Before They Become a Reason to Stop

Gastrointestinal side effects are the leading cause of early discontinuation. Nausea, in particular, tends to peak during the initial weeks of therapy and during each dose escalation. For many people, it is temporary and manageable. For others who do not receive guidance, it becomes the reason they stop.

Several strategies reliably reduce GLP-1-related nausea:

Slow dose titration. The standard titration schedules (four-week increments for semaglutide, four-week increments for tirzepatide) exist precisely to minimize gastrointestinal burden. Rushing through dose increases or skipping titration steps significantly raises the likelihood of intolerable nausea. If you are experiencing persistent nausea, speak with your provider about extending your current dose level before moving up.

Food choices. High-fat, fried, and heavily spiced foods are the most common nausea triggers on GLP-1 therapy. Eating smaller portions more frequently, avoiding foods that slow gastric emptying, and staying well-hydrated all reduce symptom severity.

Timing of the dose. Many people find that injecting semaglutide or tirzepatide before bed reduces the peak of nausea (which typically arrives 8 to 12 hours post-injection) to the sleeping hours.

If nausea is severe, persistent beyond four to six weeks, or accompanied by vomiting, contact your prescriber. Dose adjustments or a longer hold at the current level are appropriate clinical interventions, not failure.

For a full guide to managing GLP-1 side effects, see [How to Manage Nausea on Semaglutide](/resources/semaglutide-nausea-how-to-manage) and [How to Manage Nausea on Tirzepatide](/resources/tirzepatide-nausea-how-to-manage).

---

Factor 2: Pairing GLP-1 with Structured Lifestyle Changes

GLP-1 medications reduce hunger and increase satiety. They do not automatically direct your body toward optimal outcomes in terms of body composition, cardiovascular health, or long-term metabolic function. What you eat and how you move while on these medications shapes the quality of your results, not just the quantity.

A 2026 retrospective program review published in Obesity Science and Practice evaluated a structured lifestyle intervention (the TouchCare Method) applied to patients receiving GLP-1 therapy. The intervention combined mobile health technology with individualized nutrition therapy and progressive strength training. Patients who remained adherent to the program for 12 months achieved clinically significant weight loss while preserving skeletal muscle mass and improving cardiometabolic markers. [4]

This matters because GLP-1 medications, like most weight-loss interventions, cause some loss of lean muscle mass alongside fat. The patients who actively countered this through protein-focused nutrition and resistance exercise maintained better body composition outcomes.

Practically, this means two things:

1. Prioritize protein. Aim for 1.2 to 1.6 grams of protein per kilogram of body weight daily. Protein provides the amino acids your muscles need to maintain themselves during a caloric deficit. For the full breakdown, see [How Much Protein Do You Need on GLP-1 Medications](/resources/protein-intake-glp1-medications).
2. Include resistance training. Even two sessions of strength training per week substantially reduces lean mass loss during weight loss therapy. You do not need a structured gym program. Bodyweight exercises, resistance bands, and walking with loaded packs all qualify.

---

Factor 3: Setting Expectations That Match the Science

One underappreciated predictor of adherence is whether your expectations align with reality. Patients who expect rapid, linear weight loss are more likely to feel discouraged during plateau phases and to discontinue therapy before reaching their goals.

Here is what to expect from a realistic timeline:

Weeks 1 to 4. Little to no weight loss is common. Your body is adjusting to the medication. Nausea and appetite suppression may be noticeable, but the scale often does not reflect this yet.

Months 1 to 3. Most people begin to see measurable weight loss in this window, typically one-half to one pound per week on average. Early response during this phase is a reasonable indicator of your overall response trajectory.

Months 3 to 12. Weight loss continues, though the rate slows as caloric intake and expenditure approach a new equilibrium. Plateaus are a normal part of the process, not a sign that the medication has stopped working.

For context on why plateaus occur and how to navigate them, see [Why You Might Hit a GLP-1 Weight Loss Plateau](/resources/glp1-weight-loss-plateau).

Beyond 12 months. The STEP 4 trial demonstrated that patients who continued semaglutide 2.4 mg (the branded Wegovy formulation) after initial weight loss maintained their results, while those who switched to placebo regained a significant portion of their lost weight. That trial studied the FDA-approved branded product, not compounded semaglutide; outcomes for compounded formulations have not been independently studied. GLP-1 medications are a long-term treatment for a long-term condition, not a finite course.

---

Factor 4: Consistent Medical Oversight

The same 2026 discontinuation study found that patients in specific demographic groups had significantly higher odds of stopping therapy early. Lack of individualized support and follow-up emerged as a recurring theme in real-world discontinuation data. [1]

The patients who achieve the best results are those who stay in regular contact with their prescriber. This contact serves several functions:

• Dose titration guidance. Determining whether to hold at a given dose, advance to the next level, or decrease due to side effects requires provider input. Self-managing dosing without clinical guidance increases the risk of both undertreating (slow progress) and overtreating (unnecessary side effects).
• Objective progress tracking. Tracking weight, waist circumference, and relevant metabolic markers over time provides data your provider uses to assess whether the medication is working and at what dose it is most effective for you.
• Motivation and accountability. Regular check-ins provide structure. Studies consistently show that patients in clinician-monitored weight management programs maintain adherence at higher rates than those managing independently.

Telehealth platforms like Prescriva exist to make this level of ongoing support accessible and affordable. Your prescriber is a key member of your success team, not just a signature on a prescription.

---

Factor 5: Addressing the Cost Barrier

Cost was the second most common reason for discontinuation in the Van Laren 2026 analysis, cited by 14.4% of patients who stopped therapy. [1] For many people, the out-of-pocket price of branded GLP-1 medications places consistent use out of reach.

Compounded semaglutide and tirzepatide, prepared by licensed 503A compounding pharmacies, offer a significantly more accessible price point for patients who qualify. These compounded formulations contain the same active pharmaceutical ingredients as the branded versions and are prepared under state pharmacy board oversight.

For more information on compounded options and how to evaluate them, see [What Is Compounded Semaglutide?](/resources/compounded-semaglutide-what-it-is) and [What Is Compounded Tirzepatide?](/resources/compounded-tirzepatide-guide).

---

The Bottom Line

Succeeding on GLP-1 medications is not simply a matter of willpower. The data point to five concrete factors: managing side effects so you can stay on therapy, pairing the medication with structured nutrition and exercise, setting realistic expectations about the timeline, staying connected to your prescriber, and having a sustainable plan for covering costs.

The patients who achieve 15% to 20% weight loss are not always biologically different from those who discontinue early. In many cases, they simply received better support and had systems in place that made consistency easier. Building those systems before you start, or reinforcing them if you have already begun, is a strategic investment in your results.

---

Ready to explore your options? [Check your eligibility](/start) and connect with a licensed Prescriva provider.

---

*This article is for educational and informational purposes only. Compounded semaglutide and tirzepatide are not FDA-approved drugs. They are prepared by 503A compounding pharmacies and prescribed by licensed healthcare providers based on individual patient assessments. Compounded semaglutide and tirzepatide are not the same as, equivalent to, or interchangeable with FDA-approved branded products (Wegovy, Ozempic, Mounjaro, Zepbound). Clinical trial data cited in this article (STEP 1, STEP 4) refers to FDA-approved branded semaglutide formulations and may not reflect outcomes from compounded preparations. Individual results vary. Consult your healthcare provider before starting any medication.*

---

Sources

1. Van Laren J, Friesleben C, Gershovich O, et al. Characterisation of real-world patients who discontinued a glucagon-like peptide-1 agonist. *Diabetes Obes Metab.* 2026. PMID: 41713959
2. Thomsen RW, Mailhac A, Løhde JB, et al. Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies. *Diabetes Obes Metab.* 2025. PMID: 40196933
3. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. *N Engl J Med.* 2021;384(11):989-1002. PMID: 33567185
4. Edens ES, Falise H, Smith R, et al. Optimizing obesity management with GLP-1 agonist medication through mobile health technology, nutrition therapy, and progressive strength training: a retrospective program review. *Obes Sci Pract.* 2026. PMID: 41947826